Letter to the editorClinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
References (5)
- et al.
GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study
Mayo Clin Proc
(2020) - et al.
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Blood
(2019)
There are more references available in the full text version of this article.
Cited by (1)
Potential Competing Interests: The authors report no potential competing interests.
© 2021 Mayo Foundation for Medical Education and Research